Contact
searchSearch
HMP Global
Login

Gastrointestinal Cancer Specialty Channel

Gastrointestinal Cancer
Specialty Channel
FDA Approval
FDA Approves Pembrolizumab for Patients With HER2-Positive, PD-L1 Expressing Gastric or Gastroesophageal Junction Adenocarcinoma
03/19/2025
Stephanie Holland
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the...
03/19/2025
Oncology
News
Perioperative Chemotherapy Improves Survival for Patients with Resectable Esophageal Cancer
01/29/2025
Stephanie Holland
According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.
According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.
According to results from a...
01/29/2025
Oncology
Conference Coverage
Addition of Evorpacept Shows Promise for Patients With HER2-Positive Gastric or Gastroesophageal Junction Cancer
01/24/2025
Allison Casey
According to the phase 2 ASPEN-06 results, the addition of evorpacept to trastuzumab, ramucirumab, and paclitaxel showed promise for patients with HER2-positive gastric or gastroesophageal junction cancer.
According to the phase 2 ASPEN-06 results, the addition of evorpacept to trastuzumab, ramucirumab, and paclitaxel showed promise for patients with HER2-positive gastric or gastroesophageal junction cancer.
According to the phase 2...
01/24/2025
Oncology
Conference Coverage
Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Advanced Esophageal Squamous Cell Carcinoma
01/24/2025
Allison Casey
According to the phase 3 SCIENCE trial, neoadjuvant chemoradiotherapy with or without sintilimab significantly improved pathological complete response rates compared with neoadjuvant chemotherapy with sintilimab for patients with esophageal...
According to the phase 3 SCIENCE trial, neoadjuvant chemoradiotherapy with or without sintilimab significantly improved pathological complete response rates compared with neoadjuvant chemotherapy with sintilimab for patients with esophageal...
According to the phase 3 SCIENCE...
01/24/2025
Oncology
Conference Coverage
Addition of Trastuzumab to Chemotherapy for HER2-Positive Gastric Cancers
01/24/2025
Allison Casey
According to results from a phase 2 trial, following the amendment of chemotherapy regimen to FLOT, the addition of trastuzumab with or without pertuzumab did not improve progression-free survival or overall survival for patients with...
According to results from a phase 2 trial, following the amendment of chemotherapy regimen to FLOT, the addition of trastuzumab with or without pertuzumab did not improve progression-free survival or overall survival for patients with...
According to results from a...
01/24/2025
Oncology
Conference Coverage
NALIRIFOX Dose Reductions Maintain Overall Survival in Metastatic Pancreatic Cancer
01/23/2025
Allison Casey
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory...
01/23/2025
Oncology
News
FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer
12/20/2024
Allison Casey
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA...
12/20/2024
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
FDA Approval
FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors
10/18/2024
Stephanie Holland
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Conference Coverage
First-Line Retifanlimab Added to Standard of Care Chemotherapy Significantly Improves PFS in Anal Cancer
09/14/2024
Janelle Bradley
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3...
09/14/2024
Oncology
News
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin Showed Promise for Patients With Advanced Cholangiocarcinoma
08/09/2024
Stephanie Holland
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the...
08/09/2024
Oncology

News

FDA Approval
FDA Approves Pembrolizumab for Patients With HER2-Positive, PD-L1 Expressing Gastric or Gastroesophageal Junction Adenocarcinoma
03/19/2025
Stephanie Holland
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the...
03/19/2025
Oncology
News
Perioperative Chemotherapy Improves Survival for Patients with Resectable Esophageal Cancer
01/29/2025
Stephanie Holland
According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.
According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.
According to results from a...
01/29/2025
Oncology
Conference Coverage
Addition of Evorpacept Shows Promise for Patients With HER2-Positive Gastric or Gastroesophageal Junction Cancer
01/24/2025
Allison Casey
According to the phase 2 ASPEN-06 results, the addition of evorpacept to trastuzumab, ramucirumab, and paclitaxel showed promise for patients with HER2-positive gastric or gastroesophageal junction cancer.
According to the phase 2 ASPEN-06 results, the addition of evorpacept to trastuzumab, ramucirumab, and paclitaxel showed promise for patients with HER2-positive gastric or gastroesophageal junction cancer.
According to the phase 2...
01/24/2025
Oncology
Conference Coverage
Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Advanced Esophageal Squamous Cell Carcinoma
01/24/2025
Allison Casey
According to the phase 3 SCIENCE trial, neoadjuvant chemoradiotherapy with or without sintilimab significantly improved pathological complete response rates compared with neoadjuvant chemotherapy with sintilimab for patients with esophageal...
According to the phase 3 SCIENCE trial, neoadjuvant chemoradiotherapy with or without sintilimab significantly improved pathological complete response rates compared with neoadjuvant chemotherapy with sintilimab for patients with esophageal...
According to the phase 3 SCIENCE...
01/24/2025
Oncology
Conference Coverage
Addition of Trastuzumab to Chemotherapy for HER2-Positive Gastric Cancers
01/24/2025
Allison Casey
According to results from a phase 2 trial, following the amendment of chemotherapy regimen to FLOT, the addition of trastuzumab with or without pertuzumab did not improve progression-free survival or overall survival for patients with...
According to results from a phase 2 trial, following the amendment of chemotherapy regimen to FLOT, the addition of trastuzumab with or without pertuzumab did not improve progression-free survival or overall survival for patients with...
According to results from a...
01/24/2025
Oncology
Conference Coverage
NALIRIFOX Dose Reductions Maintain Overall Survival in Metastatic Pancreatic Cancer
01/23/2025
Allison Casey
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
According to an exploratory...
01/23/2025
Oncology
News
FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer
12/20/2024
Allison Casey
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA...
12/20/2024
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
FDA Approval
FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors
10/18/2024
Stephanie Holland
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Conference Coverage
First-Line Retifanlimab Added to Standard of Care Chemotherapy Significantly Improves PFS in Anal Cancer
09/14/2024
Janelle Bradley
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3...
09/14/2024
Oncology

Interactive Features

Quiz
Quiz: Which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
10/17/2022
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy...
10/17/2022
Oncology
Test Your Knowledge
Quiz: Identifying Biliary Tract Cancers
09/08/2021
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon...
09/08/2021
Oncology
Quiz
Quiz: Does Atorvastatin-Metformin Combo Reduce HCC Progression?
08/09/2021
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
Quiz: Does Infigratinib Yield a Survival Benefit in Patients with Cholangiocarcinoma and FGFR2 Fusions?
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology
Test Your Knowledge
Quiz: Is Avapritinib a Treatment Option for Patients with Unresectable PDGFRA D842V-Mutant GIST?
08/21/2020
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology
Test Your Knowledge
Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?
06/22/2020
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma...
06/22/2020
Oncology
Test Your Knowledge
Quiz: Should Pembrolizumab Be New Standard of Care for MSI-H/dMMR Metastatic CRC?
06/04/2020
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab...
06/04/2020
Oncology

Recent News

FDA Approval
FDA Approves Pembrolizumab for Patients With HER2-Positive, PD-L1 Expressing Gastric or Gastroesophageal Junction Adenocarcinoma
03/19/2025
Stephanie Holland
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...
Based on results from the...
03/19/2025
Oncology
News
Perioperative Chemotherapy Improves Survival for Patients with Resectable Esophageal Cancer
01/29/2025
Stephanie Holland
According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.
According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.
According to results from a...
01/29/2025
Oncology
News
FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer
12/20/2024
Allison Casey
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA...
12/20/2024
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
FDA Approval
FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors
10/18/2024
Stephanie Holland
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
News
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin Showed Promise for Patients With Advanced Cholangiocarcinoma
08/09/2024
Stephanie Holland
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.
According to results from the...
08/09/2024
Oncology
News
Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
News
Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
Conference Coverage
Randomized Study Demonstrates Efficay of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors
01/19/2024
Stephanie Holland
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use